Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo
- 1 June 1993
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 45 (12) , 2417-2424
- https://doi.org/10.1016/0006-2952(93)90222-i
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- A comparison of the iron-clearing properties of 1,2-dimethyl-3- hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamineBlood, 1992
- Oral iron chelation is here.BMJ, 1991
- Iron‐Melanin Interaction and Lipid Peroxidation: Implications for Parkinson's DiseaseJournal of Neurochemistry, 1991
- Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian BrainsJournal of Neurochemistry, 1991
- Rationale for Selective COMT Inhibitors as Adjuncts in the Drug Treatment of Parkinson's DiseaseBasic & Clinical Pharmacology & Toxicology, 1990
- Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's DiseaseJournal of Neurochemistry, 1989
- 2 The development of iron chelating drugsBailliere's Clinical Haematology, 1989
- Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's DiseaseJournal of Neurochemistry, 1989
- Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's diseaseNature, 1988
- Catechol O-methyltransferase. 4. In vitro inhibition by 3-hydroxy-4-pyrones, 3-hydroxy-2-pyridones, and 3-hydroxy-4-pyridonesJournal of Medicinal Chemistry, 1973